FFA
IMDX

Farther Finance Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Farther Finance Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6 Hold
1
– – ﹤0.01% 5943
2026
Q1 		$3 Buy
+1
New +$6 ﹤0.01% 5728

Other funds holding IMDX

FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
PSB
Piscataqua Savings Bank Portsmouth, New Hampshire $148M AUM 32.61% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return

Farther Finance Advisors's IMDX Position: Q2 2026 in Review

Farther Finance Advisors held its Insight Molecular Diagnostics (IMDX) position steady in Q2 2026 at 1 share worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #5943.

Farther Finance Advisors first reported a position in IMDX in Q1 2026 and has held it in 2 quarters since. 6 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Farther Finance Advisors held 1 share of Insight Molecular Diagnostics worth $6 as of Q2 2026.
  • Farther Finance Advisors left its Insight Molecular Diagnostics share count unchanged in Q2 2026.
  • Insight Molecular Diagnostics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5943 holding.
  • Farther Finance Advisors first reported a position in Insight Molecular Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • 6 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.